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methotrexate both in severe and highly active RA. METHODS:
A lifetime deterministic Markov model was developed compar-
ing two treatment sequences within two hypothetical cohorts of
patients. Five to six treatment sequences were considered in each
arm. Patients switched to the next sequence in case of lack of
effectiveness or in case of severe adverse events. Patients’ health
status was deﬁned by the Health Assessment Questionnaire
(HAQ), scale which demonstrated strong links with mortality
and quality of life. Scores were updated at every six-month model
cycles. Treatment failure occurred if the score did not improve by
0.35 point over the cycle. HAQ scores were converted into utility
coefﬁcients. Effectiveness data (HAQ progression, serious
adverse events and mortality) were derived from TEMPO trial
and literature. Only direct medical costs were considered.
Resource use was estimated through published data and expert
opinion. Costs were derived from French ofﬁcial sources. Sensi-
tivity analyses were performed on main model parameters.
RESULTS: The results showed that QALYs (Quality-Adjusted
Life-Years) were increased respectively in severe and highly active
RA by 0.98 (9.10vs8.12) and 0.73 (10.52vs9.78) in patients
treated with etanercept as 1st line compared with etanercept as
2nd line. The lifetime costs per patient were respectively in severe
and highly active RA €214,327 and €233,262 with etanercept as
1st line and €190,236 and €211,148 with etanercept as 2nd line
agent. Incremental cost-effectiveness ratios (ICER) were respec-
tively in severe and highly active RA: €24,655 and €30,199 per
QALY. Ratios ranged from €10,784 to €83,174 per QALY in
one-way sensitivity analyses. CONCLUSIONS: Treatment
sequence including etanercept as 1st line may be cost-effective in
the management of severe and highly active RA in France with
ICER fallen within acceptable range.
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OBJECTIVES: Poor compliance and failure to persist with drug
therapy are of potential economic signiﬁcance. The objective of
this study is to assess the impact of medication non-compliance
and non-persistence on economic evaluations in osteoporosis.
METHODS: A Markov microsimulation model with a lifetime
horizon and a societal perspective was used to analyse the impact
of non-adherence to biphosphonate therapy on costs (drug,
disease and total), on outcomes (Quality-Adjusted Life Years and
number of fractures saved) and on the cost-utility of biphospho-
nate therapy versus no treatment. Analyses were performed for
caucasian women aged 70 years with a diagnosis of osteoporosis
(t-score  -2.5). The relationship between compliance and frac-
ture efﬁcacy were taken from published sources and drug cost
was proportionate to compliance level. To model persistence to
therapy, we assumed that women can stop therapy after 3
months, 6 months, 1 year, 2 years or 3 years. RESULTS: Full
adherence to therapy resulted in a QALY gain of 0.0397, a 7.6%
reduction in the number of fractures and a higher cost of €383
compared to no treatment. Lower compliance was associated
with a decrease in QALY gain, a reduction in the number of
fractures saved and a higher disease cost compensated by a lower
drug cost. The cost per QALY gained for biphosphonate therapy
versus no treatment increased progressively with decreasing com-
pliance and was €9,653 €29,570 and €46,389 at 100%, 50% and
20% of compliance respectively. Realistic persistence assumption
(with full compliance) resulted in a lower QALY gain (only
0.0165) and a higher cost per QALY gained (€12,479). CON-
CLUSIONS: This study indicated that non-compliance and non-
persistence to osteoporotic therapy result not only in worsening
health outcomes, but also in a signiﬁcant change in cost-
effectiveness. Therefore, the effects of non-compliance and non-
persistence should be an integral part of economic evaluations in
osteoporosis.
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OBJECTIVES: New biologic therapies with distinct mechanisms
of action offer alternatives to rheumatologists and hope to
patients with moderate to severely active rheumatoid arthritis
(RA) and an inadequate response to anti-TNF therapy. The
objective of this study was to assess the cost-effectiveness of
abatacept and rituximab in biologic treatment sequences in
patients with RA and an inadequate response to one anti-TNF
agent. METHODS: An advanced simulation model was devel-
oped to assess the cost-effectiveness of two biologic strategies in
etanercept inadequate-responders: Strategy A—abatacept fol-
lowed by adalimumab (in case of an inadequate response to
abatacept); Strategy B—rituximab followed by adalimumab (in
case of an inadequate response to rituximab). Two clinically
relevant effectiveness endpoints were used: low disease activity
state (LDAS) (DAS28 3.2) and remission (DAS28 <2.6). Effec-
tiveness estimates for abatacept and rituximab were derived
from published pivotal trials and long-term extension studies,
assuming similar patient populations. Overall effectiveness was
expressed in theoretical expected number of days (TEND) under
remission or LDAS for each sequence after 2 years. French RA
direct medical costs were derived from a costing model based on
DAS28 categories. Using 4 ¥ 6-month cycles, drug costs were
estimated based on recommended dosing. Assuming a sustained
response over 6-month cycles, the rituximab re-treatment inter-
val was set at 6 months. Monte-Carlo simulations generated
mean values and standard deviations of costs, effectiveness and
mean cost-effectiveness over 2 years. Signiﬁcance tests were
performed to conﬁrm differences. RESULTS: Using the LDAS
endpoint, Strategy A (abatacept as second biologic agent) was
signiﬁcantly more efﬁcacious over 2 years versus (vs) Strategy B
(rituximab as second biologic agent), with 134 vs 107 TEND
under LDAS (p < 0.01). Mean cost-effectiveness ratios showed
signiﬁcantly lower overall medical costs per TEND under LDAS
with Strategy A vs Strategy B (€212 vs €234; p < 0.01). Using the
remission endpoint, Strategy A (abatacept as second biologic
agent) was signiﬁcantly more efﬁcacious over 2 years vs Strategy
B (rituximab as second biologic agent), with 61 vs 37 TEND
under remission (p < 0.01). Mean cost-effectiveness ratios
showed signiﬁcantly lower overall medical costs per TEND
under remission with Strategy A vs Strategy B (€446 vs €642;
p < 0.01). CONCLUSIONS: This innovative and robust model is
the ﬁrst to use LDAS and remission to compare biologic strate-
gies in France, aligned with RA treatment goals. The results
suggest that when used as the second biologic agent after an
inadequate response to one anti-TNF agent, abatacept appears
signiﬁcantly more efﬁcacious and cost-effective than ritux-
imab.This innovative and robust model is the ﬁrst to use LDAS
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